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Abstract 
The expression of insulin receptor substrate-I (IRS-I) mRNA was demonstrated in rat luteal cells by Northern blot analysis, in situ 
hybridization as well as by reverse transcriptase polymerase chain reaction. Western blot with a polyclonal anti IRS-I antibody showed 
the presence of a 183 kDa protein which corresponds to the size of IRS-I reported in other tissues. Further studies were performed to 
determine whether human chorionic gonadotropin (hCG) can interact with the insulin-like growth factor-I (IGF-I) signaling pathway to 
increase tyrosine phosphorylation f IRS-I. While hCG alone was ineffective in stimulating the phosphorylation f IRS-I, IGF-I mediated 
phosphorylation f IRS-I was increased by prior exposure to hCG. These results were further confirmed by the immunoprecipitation f 
IRS-I from the lysate of hCG- and IGF-I-treated luteal cell cultures followed by Western blotting with anti-phosphotyrosine a tibody. 
Similarly, pretreatment with forskolin also increased IGF-I stimulated IRS-I phosphorylation. The increased tyrosine phosphorylation f 
IRS-I seen in response to IGF-I stimulation following treatment with either hCG or forskolin was not due to an increase in IRS-I content. 
Furthermore, IGF-I receptor tyrosine kinase activity was not affected by forskolin, suggesting that the increase in IRS-I tyrosine 
phosphorylation was not the result of an increase in its activity. Thus, we conclude that hCG/LH and IGF-I signaling pathways 
'cross-talk' to increase the levels of IRS-I tyrosine phosphorylation. The observed increase in IRS-I tyrosine phosphorylation may be the 
result of an increase in the stability of the phosphorylated form of IRS-I. 
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1. Introduction 
The function of the mammalian ovary is regulated by 
luteinizing hormone (LH) and its placental counterpart, 
human chorionic gonadotropin (hCG). The rat ovary is 
also a target issue for insulin-like growth factor-I (IGF-I) 
action [1,2]. IGF-I has been shown to act synergistically 
with hCG to increase progesterone secretion by the luteal 
cells in vitro [1,2]. Similar effects of IGF-I have also been 
reported in granulosa cells [3-6]. The mechanism(s) by 
which such synergism occurs, however, is still unclear. 
The signaling mechanism by which LH/hCG exerts its 
biological effects has been well documented. This involves 
the interaction of LH/hCG with a stimulatory guanine 
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nucleotide binding (Gs) protein coupled receptor followed 
by the activation of adenylate cyclase activity. The activa- 
tion of adenylate cyclase leads to an increase in intra- 
cellular cAMP which in turn increases cAMP-dependent 
protein kinase. In addition to its effects on cAMP, hCG 
has also been shown to stimulate phosphoinositide break- 
down, Ca 2÷ mobilization and protein kinase C activity 
[7,8], although the involvement of this process in proges- 
terone secretion, if any, has not been determined. IGF-I, by 
contrast, is known to act through the activation of the 
receptor tyrosine kinase which subsequently phospho- 
rylates tyrosine residues of protein substrates in the target 
cells. One of the known substrates for the insulin receptor 
family, insulin receptor substrate-I ( RS-I) is a cytoplasmic 
protein with a molecular size ranging from 131 to 185 kDa 
and has been shown to mediate IGF-I action [9-12]. IRS-I 
can be phosphorylated on tyrosyl residues following IGF-I 
binding to its receptor [13]. Once phosphorylated, IRS-I 
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facilitates the transduction of the stimulatory signal by 
interacting with proteins containing SH2 domains [ 13-16]. 
Since IRS-I tyrosine phosphorylation appears to be a 
key element of the IGF-I signaling system, it would be 
reasonable to hypothesize that IRS-I may serve as the site 
at which other regulatory factors modulate IGF-I action. 
The purpose of the present study was to characterize the 
expression of IRS-I in the rat ovary and to examine 
whether LH/hCG has an effect on IGF-I-mediated phos- 
phorylation of IRS-I in this tissue. The expression of IRS-I 
is demonstrated here for the first time in the rat corpus 
luteum. Furthermore, IGF-I-induced tyrosine phosphoryla- 
tion of IRS-I is increased by cAMP. 
2. Experimental procedures 
2.1. Materials 
DME/F12 medium with L-glutamine, fetal bovine 
serum, gentamycin, and nystatin were purchased from 
GIBCO (Grand Island, NY). Pregnant mare serum go- 
nadotropin (PMSG), hCG, and forskolin were purchased 
from Sigma Chemicals (St Louis, MO). Highly purified 
hCG was generously supplied by the center for Population 
Research, NICHD. Recombinant human IGF-I was a gen- 
erous gift from Eli Lilly Research Laboratories (Indianapo- 
lis, IN). All other chemicals used were of analytical grade 
obtained from commercial resources. Antiphosphotyrosine 
antibody was generously provided by Dr. Jules A. Shaffer 
of Merck, Sharpe and Dohme. IRS-I cDNA was kindly 
provided by Dr. Morris White (Harvard Medical School, 
Boston, MA). IRS-I antibody was a generous gift of Dr. 
Alan Saltiel of Parke-Davis/Warner-Lambert (Ann Arbor, 
MI). 
2.2. Methods 
Cell culture. Luteal cells were isolated from day-6 
pseudopregnant ra ovaries as described previously by our 
laboratory [1,17,18]. Briefly, immature 21-day-old 
Sprague-Dawley rats (Hadan Sprague-Dawley, Madison, 
WI) were injected s.c. wi~:h 50 IU PMSG, followed 56 h 
later by 25 IU hCG. Day zero was taken as the day of hCG 
injection. On day 6, when the cells are fully differentiated, 
the injected hCG has cleared and the steroidogenic a tivity 
is known to be maximized, the ovaries were collected, 
immediately minced and the cells dispersed with collage- 
nase. The dispersed cells were incubated for 3 h in the 
absence or presence of either hCG or forskolin in a serum 
free medium at 37°C under a water-saturated atmosphere 
of 95% air and 5% CO 2. At the end of this incubation, the 
cells were subjected to further incubations in the absence 
or presence of IGF-I for periods of time specified under 
each experiment. The viability of the cells at the time of 
plating was approx. 80%. After this final incubation, the 
cells were lysed and subjected to SDS-PAGE. The experi- 
ments were performed following 6 days after hCG treat- 
ment. 
Northern gel analysis. RNA was extracted from cul- 
tured luteal cells using a single-step method of RNA 
isolation [19] by acid guanidinium thiocyanate-phenol- 
chloroform extraction. Total RNA (30/xg/lane) was elec- 
trophoresed through a 1.2% agarose gel as described previ- 
ously [1,20]. Hybridizations were performed for 24 h at 
42°C with 2 x 107 cpm probe/20 ml hybridization solu- 
tion in the presence of 0.5 mg/ml salmon sperm DNA. 
Hybridized blots were washed successively 4 times for 15 
min each with 2 X SSC/0.1% SDS at room temperature 
(2 X SSC = 0.3 M NaC1, 0.03 M Na Citrate, pH 7.0), 
followed by an additional wash at 42°C for 1 h. The blots 
were then exposed to X-ray film (Kodak XAR-5) at - 70°C 
with intensifying screens. 
In situ hybridization. The procedures were performed as 
previously described by our laboratory [21]. Ovaries ob- 
tained on day 6 of pseudopregnancy were frozen in O.C.T. 
solution (Miles Inc. Elkhart, IN) and cut at -20°C using a 
Reichert 2800 Frigocut-N cryostat (Leica, Deerfield, IL). 
Sections of 10 /xM were fixed with paraformaldehyde 
(4%; pH 7.4) for 1 h, washed three times in phosphate- 
buffered saline (PBS) incubated with proteinase K solution 
(1 /xg/ml) at 37°C for 10 min and rinsed in DEPC-treated 
deionized water. The fixed sections were then placed in 1 
M triethanolamine (PH 8.0) to which acetic anhydride 
(final concentration, 0.25% v/v)  was added. After a 10-min 
incubation, the sections were washed in 2 X SSC for 5 
min, dehydrated in an ethanol step series (50-100%), 
air-dried and stored at -80  C until hybridization. Anti- 
sense and sense [a3SS] UTP-labeled RNA probes were 
synthesized using T3 and T7 RNA polymerase from a 548 
bp IRS-I cDNA template cloned into a Bluescript vector. 
The 548 bp IRS-I cDNA was obtained by digesting the 
IRS-I full-length cDNA clone with restriction enzymes 
XhoI and XbaI. Thirty-five microliters of hybridization 
solution [1 X Denhardt's olution, 75% formamide, 3 × 
SSC, 50 mM Na-phosphate buffer (pH 7.4), 10% Dextran 
sulfate, 200/xg/ml yeast mRNA and 1 mM DTT] contain- 
ing labeled RNA probe (1.5 X 10 6 cpm) were applied to 
the tissue sections and the sections overlaid with a cover- 
slip, sealed with rubber cement and hybridized at 55°C for 
18 h in a moist chamber. After hybridization, the sections 
were washed in 2 X SSC, RNAse treated (200 /xg/ml 
RNAse-A; 4 U/ml  RNAse-T) at 37°C for 1 h and washed 
in decreasing concentrations of SSC (2 X 0.1 SSC) at 
55°C and dehydrated through an ethanol series (50-100%) 
and dried. The slides were then processed for liquid emul- 
sion autoradiography using NTB-2 emulsion (Kodak, 
Rochester, NY). The slides were developed after 6 days 
and counterstained with hematoxylin-eosin. 
PCR analysis. The analysis was performed as described 
by Araki et al. [22]. The corresponding rat nucleotide 
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sequence for the sense and antisense primers correspond- 
ing to rat IRS-I cDNA nucleotide sequence [9] were 
1765-1781 and 1968-1985, respectively. The conditions 
for the PCR were, 1 /zg of each primer/100 /zl reaction 
mixture, denaturing at 95°C for 30 s, annealing at 5 I°C for 
30 s, and extension at 72°C for 1 min. Linear amplification 
of IRS-I mRNA was achieved using 1 /zg of luteal cell 
total RNA/reaction and 35 cycles. As a negative control, 
the reverse transcription reaction followed by PCR was 
performed without addition of RNA. To determine the 
amount of IRS-I PCR product derived from any contami- 
nating genomic DNA, the reaction was performed in the 
absence of reverse transcriptase. No PCR products were 
observed under these conditions. The PCR product was 
further characterized by digestion with MspI. 
Iodination of IGF-I and binding assay. IGF-I was la- 
beled by the chloramine-T method as described previously 
[1,23]. Briefly, 1 /xg IGF-I was mixed with 1 mCi carrier- 
free 1251 (ICN) in 100 /xl 0.5 M Na2PO 4 (pH 7.4). The 
reaction was initiated by adding 5 /xl chloramine-T (120 
/xg/ml) and allowed to incubate for 1.5 min. The reaction 
was stopped by the addition of sodium metabisulfite (200 
/xg/ml). The labeled peptide was separated from free 125I 
by chromatography as previously described [1]. This 
preparation was then stored at -20°C. Binding studies 
were performed within 4 weeks of iodination. For the 
binding assay, cell suspensions were incubated in a total 
volume of 0.1 ml binding assay buffer (50 mM Tris-HC1, 1 
mM phenylmethylsulfonyl fluoride, and 0.25% BSA, pH 
7.4) containing 125I-IGF-I (150-250 /xCi//xg protein), 
either alone (total binding) or in the presence of 200-fold 
excess of unlabeled ligand (nonspecific binding). All incu- 
bations were performed at 4 C for 16 h. After incubation, 
the receptor-bound a25I-IGF-I was separated from free 
125I-IGF-I by the addition of 1 ml pre-cooled buffer to 
each tube followed by centrifugation at 10 000 × g for 10 
rain at 4°C. The supernatants were removed by aspiration 
and the pellets counted in an automatic y-counter (Searle 
Analytic, model 1195; Searle Radiographics, Des Plaines, 
IL). The specific binding was determined by subtracting 
the nonspecific binding from the total binding. Each bind- 
ing assay was performed in replicates of six and expressed 
as mean _+ S.E.M. 
Western blotting. The luteal cells were plated in 24-well 
dishes in DME/F-12 medium containing 0.3% BSA and 
treated as described under cell culture. After the final 
incubation, the cells were immediately lysed with a 2 X 
boiling hot lysis buffer consisting of 10 mM Tris (pH 6.8); 
2% SDS; 0.2 M DTT; 10% /3-mercaptoethanol; 20% glyc- 
erol; 0.2 mM molybdate; 1 mM Na3VO4; 400 /zg/ml 
leupeptin and 200 /xg/ml aprotinin. The samples were 
then stored at -80°C until electrophoresis was carried out. 
A fraction of each sample (100 /zg protein), was separated 
by 7.5% SDS-PAGE unless specifically stated, and im- 
munoblots probed without (control) or with a polyclonal 
antiphosphotyrosine antibody (1:2000 dilution). The im- 
munoblot was analyzed using the ECL detection system 
(Amersham). 
Immunoprecipitation. The rat luteal cells (4 X 106/ml) 
plated in 35-mm dishes were pretreated without or with 
hCG (200 ng/ml) for 3 h followed by an incubation in the 
absence or presence of IGF-I (100 ng/ml) for 1 min. The 
cells were then harvested into 12 X 75 mm polypropylene 
tubes containing an equal volume of ice cold phosphate- 
buffered saline containing 2 mM orthovanadate (PBS-O). 
The cells were washed twice with PBS-O by centrifuging 
at 400 X g. Following the wash, the packed cells were 
lysed with PBS containing 1% Triton X-100, 50 mg 
sodium deoxycholate and 10 mg sodium dodecyl sulfate 
(PBSTDS). The resulting lysate was then centrifuged at 
100000Xg for 30 min. The supernatant (1 ml) was 
incubated with IRS-I affinity purified antibody (UBI; Lake 
Placid, NY) preadsorbed to protein A sepharose. The 
samples were then centrifuged at 1000 X g and subjected 
to SDS-PAGE. The gel was then transblotted onto a 
nitrocellulose filter, and a Western blot performed using 
the polyclonal antiphosphotyrosine a tibody. For negative 
controls, the immunoprecipitations were performed in the 
absence of the IRS-I antibody. 
Cell-free tyrosine kinase activity assay. Luteal cells 
were incubated in the absence or presence of forskolin 
(100 /xM) in 35-mm six-well plates. Following this incu- 
bation, the cells were treated without or with IGF-I (100 
ng/ml) for 1 min and tyrosine kinase activity was mea- 
sured by the method of Takahashi et al. [24]. Briefly, the 
reaction was stopped by adding 1 ml of ice-cold Hanks' 
balanced salt solution (HBSS; 0.3% BSA) and washed 
three times with this medium. Cells were lysed at 0°C in 
500 /zl of a lysis buffer (Triton X-100, 5 mM EDTA, 10 
/xg/ml leupeptin, 5 /xg/ml pepstatin, 20 /xg/ml phenyl- 
methylsulfonylfluride and 10 /xg/ml aprotinin) containing 
10 mM p-nitrophenyl phosphate. The lysates were tum- 
bled for 30 min at 4°C. Following centrifugation (15 000 x 
g) for 30 min at 4°C, 100 /xl of the supernatant was 
incubated with 100 /xl of WGA-agarose for 1 h. The 
reaction mixture was centrifuged and pelleted. WGA- 
agarose was washed three times with the lysis buffer 
solution, and the adsorbed proteins were eluted with 100 
/xl of 0.3 M N-acetylglucosamine. 
The WGA-adsorbed fraction (50 /xl) was preincubated 
without or with IGF-I (100 ng/ml) for 30 min at 25 C. A 
20-min cell-free phosphorylation was initiated with 25 /xl 
of reaction mixture to give a final concentration f 50 mM 
Hepes-NaOH (pH 7.6), 50 mM MgC12 500 /xM ortho- 
vanadate, 1% Triton X-100, 20 /zM [y-32p]ATP (10 
Ci/mmol), 2 mg/ml poly (Glu-Tyr) (4:1). The reaction 
was terminated by applying 30 /xl of the reaction mixture 
to GF/B  filters and extensively washed at 4°C with 10% 
trichloroacetic acid containing 10 mM sodium pyrophos- 
phate for 30 min. This was followed by two 30-min 
washes with 5% TCA. The filter was then rinsed with 
ethanol, dried, and counted in a liquid scintillation counter. 
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Tyrosine kinase activity was expressed as the orthophos- 
phate incorporated into the poly(Glu-Tyr) (4:1) during a 
20-min incubation period. 
3a 
3. Results 
3.1. IRS-I expression in the ovary 
Initial studies were conducted to examine the presence 
of IRS-I in the luteal cells. When probed with the IRS-I 
cDNA, Northern blots (Fig. 1A) showed a 10 kb transcript 
corresponding to IRS-I mRNA [9]. To further confirm the 
presence of the IRS-I transcript in the luteal cells, an 
RT-PCR analysis was pe~brmed. Lanes a and b (Fig. 1B) 
representing reactions performed in the absence of RNA 
and reverse transcriptase, respectively, did not show any 
product formation. Lane d (Fig. 1B) showed a 221 bp 
product corresponding to the expected size for IRS-I. The 
product was then digested with restriction enzyme MspI 
which cleaved the 221 bp product into 59 and 162 bp 
fragments (Fig. 1B; lane e). These results confirm the 
identity of the PCR product as the IRS-I cDNA fragment. 
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Fig. 1. (A) Northern blot analysis of 1RS-I mRNA in rat luteinized 
ovarian tissue. Total RNA was obtained as described in Section 2. The 
RNA (40 /xg) was electrophoresed through a 1.2% agarose gel as 
described in Section 2. (B) PCR analysis. One microgram of total RNA 
prepared from luteal cells was reversed transcribed into cDNA in the 
presence of the 5' and 3' primers as described in Section 2. Lanes a and b 
represent reactions performed without RNA sample and reverse transcrip- 
tase. Lane c represents the DNA 123 ladder. Lanes e and f represent 
complete PCR reactions followed by an incubation in the absence or 
presence of restriction enzyme MspI, respectively. 
_)15 
IRS.I.--~ 
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Fig. 2. Western blot analysis of IRS-I. Ovarian luteal cells were dispersed 
with collagenase and homogenized asdescribed in Section 2. Immunoblot 
analysis from samples ubjected to a 5% SDS-PAGE was performed 
using an IRS-I polyclonal antibody. 
Western blot analysis performed with a polyclonal anti- 
IRS-I antibody revealed a band of approx. 183 kDa which 
also corresponded to that of IRS-I (Fig. 2). These studies 
clearly demonstrate he presence of IRS-I in luteal cells. 
To further characterize the expression of IRS-I mRNA 
in the luteinized ovary, we performed in situ hybridization 
using 35S-labeled IRS-I antisense cRNA strand to tissue 
sections prepared from luteinized rat ovaries. Representa- 
tive sections of the in situ hybridization are shown in Fig. 
3. The light field photomicrograph of the hematoxylin-eosin 
stained section of the ovary is shown in Fig. 3a. When 
examined under dark-field (Fig. 3b), the labeled antisense 
cRNA strand hybridized predominantly to luteal cells, 
whereas substantially less hybridization was observed in 
granulosa cells and thecal layers of the follicles and the 
connective tissue surrounding the corpora lutea. Fig. 3c 
represents he sections that were hybridized with the 35S- 
labeled sense cRNA strand which as expected, did not 
hybridize to the sections. These experiments show that 
IRS-I is expressed in the corpus luteum and further con- 
firm the Northern blot data. 
3.2. Effect of lGF-I and hCG on IRS-I tyrosine phosphory- 
lation 
To examine the effects of IGF-I on IRS-I tyrosine 
phosphorylation, a time course with IGF-I was performed. 
The IRS-I phosphorylated band was not visible under these 
conditions (data not shown). Since previous studies have 
demonstrated that hCG can potentiate the effect of IGF-I 
in luteal cell progesterone s cretion [1,2], subsequent s ud- 
ies were carried out to determine whether hCG interact 
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Fig. 3. In situ hybridization of IRS-I mRNA in the rat luteinized ovary. (A) Bright-field observation of a section of the luteinized ovary. (B) Dark-field 
analysis of the same section hybridized with antisense IRS-I RNA. (C) Dark-field analysis of the tissue section hybridized with sense IRS-I RNA. 
with the IGF-I responsive pathway to increase tyrosine 
phosphorylation of IRS-I. To test the effect of hCG on 
IRS-I tyrosine phosphorylation, the cells were preincu- 
bated for 3 h without or with hCG. At the end of this 
period, the cells were incubated for an additional 0, 0.25, 
0.5, 1, 2, 5 or 10 min in the absence or presence of IGF-I. 
The levels of tyrosine phosphorylated proteins were evalu- 
ated by immunoblot analysis with a polyclonal anti-phos- 
photyrosine antibody (Fig. 4). In the absence of any treat- 
ment, several tyrosine phosphorylated bands were visible 
(Fig. 4; lane 1) but the 183 kDa band was not observed. In 
addition, when the cells were primed with hCG, the level 
of phosphorylation f these tyrosine-containing substrates 
was not affected (Fig. 4; lane 2). However, when the hCG 
primed cells were incubated with IGF-I, a distinct 
phosphorylated IRS-I band appeared with the increase in 
incubation periods (Fig. 4, lanes 3-8). IGF-I increased the 
levels of phosphorylation f the 183 kDa IRS-I protein by 
10-fold. Although tyrosine phosphorylated IRS-I was pre- 
sent in low abundance, the stimulatory effect produced by 
IGF-I was consistently reproducible. Furthermore, an hCG 
dose-response tudy showed that a maximum increase in 
the intensity of the 183 kDa phosphotyrosine band was 
seen at 100 ng/ml (Fig. 5, top panel). 
The presence of phosphorylated IRS-I protein in the 
cultured luteal cells, was further confirmed by immuno- 
precipitation studies. The cells were incubated without or 
with hCG (200 ng/ml) for 3 h followed by an incubation 
in the absence or presence of IGF-I (100 ng/ml) for 1 
min. The cells were then lysed and immunoprecipitations 
38- 
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71 
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1 2 3 4 5 6 7 8 9 1 0  
IGF-I t ime ~ur~ (rain) 
Fig. 4. Time course of the effects of IGF-I on phosphotyrosine content of rat luteal cells. The graph represents a densitometric s an of the 183 kDa band in 
lanes 2-8 of the blot that appears in the inset. The background was taken into account when doing all the densitometric s ans. The inset represents he 
immunoblot f rat luteal cells preincubated without (lane 1) or with 200 ng/ml hCG (lane 2-8) for 3 h followed by IGF-I (100 ng/ml) for 0.25, 0.5, 1.0, 
2.0, 5.0, 10.0 min (lanes 3-8, respectively). Cells were lysed and samples (100 /zg) representative of each time point subjected to 7.5% SDS-PAGE. 
Immunoblot analysis was performed using a polyclonal anti-phosphotyrosine a tibody as described in Section 2. 
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Fig. 5. Effect of hCG dose on IRS-I tyrosine phosphorylation by IGF-I in rat luteal cells (top panel). The graph represents a densitometric s an of the blot 
that appears in the inset. In the inset, the immunoblot of rat luteal cells incubated with various concentrations (0, 5, 12.5, 25, 50, 100, 200 ng/ml:  lanes 
1-7) of hCG for 3 h and treated with or without IGF-I (100 ng/ml)  for 1 min (lanes 2-7). Cells were harvested and immunoblot analysis performed as 
described in Fig. 4. Lower panel, Western blot of phosphorylated IRS-I following immunoprecipitation of IRS-I from the lysate of control, IGF-I, hCG and 
hCG pretreated IGF-I-stimulated cells. The details of the experimental design are described in Section 2. The resulting pellet was subjected to 
electrophoresis and immunoblots performed using the antiphosphotyrosine a tibody. The results are shown at the bottom of the hCG dose immunoblot. 
performed using an affinity purified IRS-I antibody and 
subjected to electrophoresis. Immunoblots were then per- 
formed with antiphosphotyrosine antibody (Fig. 5, lower 
panel). The results showed a 183 kDa band corresponding 
to that of IRS-I in lanes I and h / I  which represent cells 
treated with IGF-I alone and a combination of hCG and 
IGF-I. The tyrosine phosphorylated band was not observed 
in lane C (control) and h (hCG). These results show that 
the band in the Western blots for tyrosine phosphorylation 
studies represent tyrosine-phosphorylated IRS-I. 
~ 80-  
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Fig. 6. Effect of forskolin dose on tyrosine phosphorylation in rat luteal cells. The graph represents a densitometric s an of the blot that appears in the 
inset. In the inset, the immunoblot of rat luteal cells incubated with various concentrations (0,0.1, 1, 10, 100, 200 txM: lanes 1-6) of forskolin for 3 h and 
treated with or without IGF-I (100 ng/ml  Lanes 2-6) for 1 min is shown. Cells were processed as described in Fig. 5 and subjected to a 6% SDS-PAGE. 
Following the immunoblot analysis with the antiphosphotyrosine a tibody, the blot was stripped as described by the manufacturer and reprobed using the 
polyclonal antibody against IRS-.I described in Fig. 2. The results are shown at the bottom of the anti-phosphotyrosine immunoblot. 
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Table 1 
Effect of hCG (200 ng/ml) and forskolin (100 /xM) on IGF-I binding 
125 I-IGF-I binding K d 
(pg/100/xg membrane protein) (nM) 
Control 17.3 + 0.01 3.2 
hCG 17.7 + 0.001 n.d. * 
Forskolin 16.7 +_ 0.001 2.8 
Cells were incubated without or with hCG (200 ng/ml) and forskolin 
(100 /zM) for 3b. Following this incubation cells were harvested and 
membranes isolated as described in Section 2. * Not determined. 
To determine whether the increase in tyrosine phospho- 
rylation of IRS-I was due to increased intracellular cAMP 
production resulting from the hCG treatment, cells were 
preincubated with forskolin for 3 h, followed by IGF-I for 
1 min. To increase the resolution of the band representing 
phosphorylated IRS-I, 6% SDS-PAGE was used in these 
studies. The effect of forskolin on IRS-I tyrosine phospho- 
rylation was dose-dependent. A gradual increase of up to 
4-fold was observed when increasing concentrations of 
forskolin were used (Fig. 6, top panel) and the maximal 
response was seen at 200 /xM of forskolin. Unlike the 
previous immunoblots, most of the tyrosine-phospho- 
rylated bands in this immunoblot appeared as doublets. We 
attribute this to an artifact of the electrophoresis in this 
particular experiment since this was the only blot that 
exhibited such a pattern. Nevertheless, the results suggest 
that cAMP may mediate hCG effects on IGF-I-dependent 
tyrosine phosphorylation f IRS-I. In this study, the phos- 
phorylation of the 95 kDa /3 subunit of the IGF-I receptor 
was not detected when cAMP levels were increased. It is 
possible that the level of phosphorylation was too low to 
be detected in the immunoblot. Alternatively, cAMP may 
not be able to increase the phosphorylation of the 95 kDa 
subunit o levels that could be detected by this technique. 
3.3. Studies on the mechanism of regulation of IRS-I 
tyrosine phosphorylation by hCG and forskolin 
The mechanism by which hCG and forskolin enhance 
IGF-I dependent IRS-I phosphorylation was then pursued. 
First, we tested the possibility that an increase in the levels 
of tyrosine-phosphorylated IRS-I in forskolin-pretreated 
cells is due to an increase in IRS-I content. For this 
purpose, the blot used in the experiments described in the 
top panel of Fig. 6 was stripped and then probed with the 
IRS-I polyclonal antibody. As in the antiphosphotyrosine 
immunoblots, the band corresponding to IRS-I also ap- 
peared as doublet (Fig. 6, lower panel). However, IRS-I 
levels did not increase in response to forskolin treatment 
(Fig. 6, lower panel). To confirm these results, the cells 
were incubated for 3 h with increasing concentrations of
forskolin but without further exposure to IGF-I. The results 
again showed that IRS-I protein levels were not affected 
by cAMP (data not shown). 
Further experiments were then carried out to examine 
whether the increase in tyrosine phosphorylation of the 
183 kDa IRS-I protein was due to an increase in IGF-I 
receptor number. The cells were incubated in the absence 
or presence of either hCG or forskolin for 3 h before IGF-I 
receptor binding assays were performed. The results are 
shown on Table 1. Neither treatment affected the number 
of IGF-I receptors. 
Finally, the effect of forskolin on IGF-I receptor tyro- 
sine kinase activity was determined. To accomplish this, 
the cells were initially incubated without or with forskolin 
for 3 h. Following this incubation, the cells were incubated 
in the absence or presence of IGF-I for 1 min and then 
processed for the assay of tyrosine kinase activity. As 
shown in Table 2, pretreatment with forskolin had no 
effect on tyrosine kinase activity. The data are representa- 
tive of three independent experiments. Thus, the increase 
in tyrosine kinase activity in response to forskolin treat- 
ment does not appear to be due to an increase in tyrosine 
kinase activity, but it may be due to stabilization of 
phosphotyrosine residues. 
4. Discussion 
IRS-I has been shown to play a pivotal role in the IGF-I 
signaling system. The results presented in this study have 
documented for the first time the presence of IRS-I in the 
luteinized ovary and that both hCG and forskolin can 
increase IGF-I-mediated phosphorylation of IRS-I. The 
expression of IRS-I in this tissue was evidenced by the 
Table 2 
Effect of forskolin on IGF-I stimulated tyrosine kinase activity 
First incubation: forskolin (3 h) - + - + 
Second incubation: IGF-I (1 min) - - + + 
Cell free assay Phosphotransferase ctivity 
(Treatments) (pmol of [ 3/- 32 p] ATP transferred//zg protein/20 min) 
- IGF-I 0.39 5:0.03 0.54 + 0.07 1.26 + 0.02 1.13 + 0.06 
+ IGF-I 0.61 5:0.06 0.83 5:0.07 2.23 5:0.01 1.90 + 0.04 
Luteal cells were pretreated without or with forskolin (10 /xM) for 3 h. At the end of this incubation, they were incubated without or with IGF-I (100 
ng/ml) for 1 min. The cells were then solubilized in the lysis buffer and centrifuged. Tyrosine kinase was then partially purified and the cell free assay 
performed, as described in Section 2. 
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results obtained with the Northern blot, in situ hybridiza- 
tion, immunoprecipitation and Western blot analyses. The 
presence of the IRS-I mRNA transcript was further con- 
firmed by RT-PCR. These findings suggest that IRS-I may 
be an important component of the IGF-I signaling pathway 
in the ovarian tissue. 
An interesting aspect of this study is the demonstration 
that hCG and IGF-I can interact to stimulate IRS-I tyrosine 
phosphorylation i  luteal cells. The increase in IGF-I-de- 
pendent tyrosine phospho):ylation f IRS-I observed in the 
hCG and forskolin-primed luteal cells supports the hypoth- 
esis that the hCG-responsive second messenger, cAMP, 
cross-talks with the IGF-I responsive system to enhance its 
action. This is consistent with the findings in other sys- 
tems. For example, in FRTL-5 cells, the cAMP-responsive 
system has been shown to interact with that of IGF-I to 
increase the phosphorylation of a 175 kDa protein [24]. 
This event was shown to associate with a synergistic 
stimulation of FRTL-5 cell proliferation [24]. However, 
unlike FRTL-5 cells, luteal cells are fully differentiated 
cells whose primary role is to secrete progesterone and as 
such, these cells do not undergo mitosis. These observa- 
tions suggest hat the increase in IRS-I phosphorylation is 
not only associated with an increase in the mitogenic 
activity of the cells. It appears that in fully differentiated 
cells such as the one employed here, the increase in IRS-I 
phosphorylation may be associated with an increase in 
differentiating processes which has been shown to be 
regulated by IGF-I [25-27]. Thus, the results of our study 
along with those reported in nonsteroidogenic cells strongly 
suggest hat IRS-I may serve as a point of interaction for 
both pathways to amplify their biological response. 
As expected, our study demonstrated that the effect of 
hCG on IRS-I tyrosine phosphorylation is mediated by 
intracellular cAMP. The mechanism by which LH/hCG 
increases tyrosine phosphorylation f IRS-I as observed in 
this study does not appear to involve an increase in IRS-I 
protein content, IGF-I receptor number, or tyrosine kinase 
activity. Since none of these three factors were affected by 
forskolin, which is known to increase cellular cAMP lev- 
els, it appears that cAMP effects are exerted at a step 
beyond the activation of tyrosine kinase. These observa- 
tions suggest hat hCG enhances IRS-I tyrosine phospho- 
rylation by increasing the stability of tyrosine-phospho- 
rylated IRS-I. Cyclic AMP could increase the stability of 
tyrosine-phosphorylated IRS-I through several mecha- 
nisms. These include alterations of substrate conformation, 
inhibition of protein tyrosine phosphatases, increased acti- 
vation of tyrosine-specific protein kinases by cAMP or a 
combination of these processes. In this context, it is inter- 
esting to note that protein tyrosine phosphatase 2C (PTP2C) 
has been shown to be responsible for the hydrolysis of 
IRS-I phosphotyrosine re,;idues [28,29]. This suggests that 
protein tyrosine phosphatases, such as PTP2C, could play 
a key role in regulating IGF-I function. Whether this type 
of regulation exists in the ovary remains to be explored. 
Studies by Giorgetti et al. [13] and Skolnik et al. [14] 
have suggested that IRS-I, when phosphorylated, can func- 
tion as a docking protein that increases the activity of 
signaling molecules including phosphatidylinositol 3' ki- 
nase and Grb2. These molecules are intermediate in the 
IGF-I responsive pathway and play a role in the regulation 
of gene expression and DNA synthesis [30,31]. It is not 
currently known, however, whether these molecules are 
also involved in the regulation of luteal cell steroidogene- 
sis. Nevertheless, the evidence presented here suggests that 
the IGF-I and hCG/LH responsive pathways converge to 
increase the levels of tyrosine phosphorylated IRS-I. This 
could, in turn, enhance IGF-I effects on the activation of 
signaling cascades responsible for mediating IGF-I action. 
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